Did Insmed Release Shaky Data for its Arikace Drug?

Source: pharmamanufacturing.com

Oct 24, 2013

TheStreet.com

Insmed Inc. claims the phase III study demonstrated the still-experimental Arikace was just as effective as currently approved Novartis' TOBI in treating bacterial lung infections afflicting cystic fibrosis patients, however, the recently published data does not support these claims.

After the drugmaker released a poster presentation outlining this effectiveness, critics suggested that had Insmed relied on the intent-to-treat population rather than the findings from the per protocol population, its drug may not have achieved the primary endpoint.

Further igniting suspicion is the fact that the company chose to publicize the Arikace phase III results during a self-imposed quiet period ahead of third-quarter financial results to be released on Nov. 5th.

Read the full analysis from TheStreet.com

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments